Restricted accessBrief reportFirst published online 2017-1
A Preliminary Study of Genetic Variation in the Dopaminergic and Serotonergic Systems and Genome-Wide Additive Genetic Effects on Depression Severity and Treatment Response
Major depression is a heritable disorder that is commonly treated with selective serotonin reuptake inhibitors. However, no study has quantified the overlap in genetic effects between pretreatment depression severity and treatment response and the extent to which genetic effects could be attributed to variation in the dopaminergic and serotonergic systems (DA/5-HT). Data (N=1618) from the clinician-rated Hamilton Rating Scale of Depression and the clinician-rated Quick Inventory of Depressive Symptomatology were obtained from participants of European ancestry in the Sequenced Treatment Alternatives to Relieve Depression clinical trial. Genetic variants explained 31%–64% of the variance across assessments of pretreatment depression severity and treatment response. However, effects from the DA/5-HT systems genes were negligible. There was also limited evidence for genetic overlap for pretreatment depression severity and treatment response. Despite the clear genetic contributions to these depression phenotypes, different genetic factors may contribute to depression severity and treatment response.
AdkinsD. E.AbergK.McClayJ. L.HettemaJ. M.KornsteinS. G.BukszarJ.van den OordE. J. (2010). A genomewide association study of citalopram response in major depressive disorder—A psychometric approach. Biological Psychiatry, 68(6), e25–e27. doi:10.1016/j.biopsych.2010.05.018.
2.
ChekroudA. M.ZottiR. J.ShehzadZ.GueorguievaR.JohnsonM. K.TrivediM. H.. . . CorlettP. R. (2016). Cross-trial prediction of treatment outcome in depression: A machine learning approach. The Lancet: Psychiatry, 3(3), 243–250. doi:10.1016/S2215-0366(15)00471-X.
3.
FlintJ.KendlerK. S. (2014). The genetics of major depression. Neuron, 81(3), 484–503. doi:10.1016/j.neuron.2014.01.027.
4.
FournierJ. C.DeRubeisR. J.HollonS. D.DimidjianS.AmsterdamJ. D.SheltonR. C.FawcettJ. (2010). Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA: The Journal of the American Medical Association, 303(1), 47–53. doi:10.1001/jama.2009.1943.
5.
FranchiniL.SerrettiA.GasperiniM.SmeraldiE. (1998). Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. Journal of Psychiatric Research, 32(5), 255–259. doi:10.1016/S0022-3956(98)00004-1.
6.
GarriockH. A.KraftJ. B.ShynS. I.PetersE. J.YokoyamaJ. S.JenkinsG. D.. . . HamiltonS. P. (2010). A genomewide association study of citalopram response in major depressive disorder. Biological Psychiatry, 67(2), 133–138. doi:10.1016/j.biopsych.2009.08.029.
7.
GessaG. L.DevotoP.DianaM.FloreG.MelisM.PistisM. (2000). Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 22(6), 642–649. doi: 10.1016/S0893-133X(00)00087-7.
8.
HamiltonM. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23, 56–62.
9.
HirschfeldR. M. (2000). History and evolution of the monoamine hypothesis of depression. The Journal of Clinical Psychiatry, 61(Suppl. 6), 4–6.
10.
HunterA. M.LeuchterA. F.PowerR. A.MuthenB.McGrathP. J.LewisC. M.. . . HamiltonS. P. (2013). A genome-wide association study of a sustained pattern of antidepressant response. Journal of Psychiatric Research, 47(9), 1157–1165. doi:10.1016/j.jpsychires.2013.05.002.
11.
KesslerR. C. (2012). The costs of depression. The Psychiatric Clinics of North America, 35(1), 1–14. doi:10.1016/j.psc.2011.11.005.
12.
KesslerR. C.AvenevoliS.CostelloJ.GreenJ. G.GruberM. J.McLaughlinK. A.. . . MerikangasK. R. (2012). Severity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. Archives of General Psychiatry, 69(4), 381–389. doi:10.1001/archgenpsychiatry.2011.1603.
13.
KesslerR. C.BrometE. J. (2013). The epidemiology of depression across cultures. Annual Review of Public Health, 34, 119–138. doi:10.1146/annurev-publhealth-031912-114409.
14.
KesslerR. C.van LooH. M.WardenaarK. J.BossarteR. M.BrennerL. A.CaiT.. . . ZaslavskyA. M. (2016). Testing a machine-learning algorithm to predict the persistence and severity of major depressive disorder from baseline self-reports. Molecular Psychiatry. doi:10.1038/mp.2015.198.
15.
KleinD. N.LewinsohnP. M.SeeleyJ. R.RohdeP. (2001). A family study of major depressive disorder in a community sample of adolescents. Archives of General Psychiatry, 58(1), 13–20.
16.
KrishnanV.NestlerE. J. (2010). Linking molecules to mood: New insight into the biology of depression. The American Journal of Psychiatry, 167(11), 1305–1320. doi:10.1176/appi.ajp.2009.10030434.
17.
LajeG.McMahonF. J. (2011). Genome-wide association studies of antidepressant outcome: A brief review. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35(7), 1553–1557. doi:10.1016/j.pnpbp.2010.11.031.
18.
LeeS. H.DeCandiaT. R.RipkeS.YangJ.SullivanP. F.GoddardM. E.. . . WrayN. R. (2012). Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nature Genetics, 44(3), 247–250. doi:10.1038/ng.1108.
19.
LeeS. H.YangJ.GoddardM. E.VisscherP. M.WrayN. R. (2012). Estimation of pleiotropy between complex diseases using single-nucleotide polymorphism-derived genomic relationships and restricted maximum likelihood. Bioinformatics, 28(19), 2540–2542. doi:10.1093/bioinformatics/bts474.
20.
LubkeG. H.HottengaJ. J.WaltersR.LaurinC.de GeusE. J.WillemsenG.. . . BoomsmaD. I. (2012). Estimating the genetic variance of major depressive disorder due to all single nucleotide polymorphisms. Biological Psychiatry, 72(8), 707–709. doi:10.1016/j.biopsych.2012.03.011.
21.
MarstellerD. A.Barbarich-MarstellerN. C.PatelV. D.DeweyS. L. (2007). Brain metabolic changes following 4-week citalopram infusion: Increased 18FDG uptake and gamma-amino butyric acid levels. Synapse, 61(11), 877–881. doi:10.1002/syn.20428.
22.
MelisM.PerraS.MuntoniA. L.PillollaG.LutzB.MarsicanoG.. . . PistisM. (2004). Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 24(47), 10707–10715. doi:10.1523/JNEUROSCI.3502-04.2004.
23.
OlfsonM.MarcusS. C.DrussB.ElinsonL.TanielianT.PincusH. A. (2002). National trends in the outpatient treatment of depression. JAMA: The Journal of the American Medical Association, 287(2), 203–209.
24.
PowerR. A.KeersR.NgM. Y.ButlerA. W.UherR.Cohen-WoodsS.. . . LewisC. M. (2012). Dissecting the genetic heterogeneity of depression through age at onset. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, 159B(7), 859–868. doi:10.1002/ajmg.b.32093.
25.
PurcellS.NealeB.Todd-BrownK.ThomasL.FerreiraM. A.BenderD.. . . ShamP. C. (2007). PLINK: A tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics, 81(3), 559–575. doi:10.1086/519795.
26.
RubinoT.PriniP.PiscitelliF.ZamberlettiE.TruselM.MelisM.. . . ParolaroD. (2015). Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Neurobiology of Disease, 73, 60–69. doi:10.1016/j.nbd.2014.09.015.
27.
RuheH. G.MasonN. S.ScheneA. H. (2007). Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: A meta-analysis of monoamine depletion studies. Molecular Psychiatry, 12(4), 331–359. doi:10.1038/sj.mp.4001949.
RushA. J.TrivediM. H.IbrahimH. M.CarmodyT. J.ArnowB.KleinD. N.. . . KellerM. B. (2003). The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biological Psychiatry, 54(5), 573–583.
30.
RushA. J.TrivediM. H.WisniewskiS. R.NierenbergA. A.StewartJ. W.WardenD.. . . FavaM. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. The American Journal of Psychiatry, 163(11), 1905–1917. doi:10.1176/appi.ajp.163.11.1905.
31.
SerrettiA.FranchiniL.GasperiniM.RampoldiR.SmeraldiE. (1998). Mode of inheritance in mood disorder families according to fluvoxamine response. Acta Psychiatrica Scandinavica, 98(6), 443–450.
32.
SteigerJ. H.FouladiR. T. (1997). Noncentrality interval estimation and the evaluation of statistical models. In HarlowL. L.MulaikS. A.SteigerJ. H. (Eds.), What if there were no significance tests? (pp. 221–257). Mahwah, NJ: Lawrence Erlbaum Associates.
33.
TanseyK. E.GuipponiM.HuX.DomeniciE.LewisG.MalafosseA.. . . UherR. (2013). Contribution of common genetic variants to antidepressant response. Biological Psychiatry, 73(7), 679–682. doi:10.1016/j.biopsych.2012.10.030.
34.
TennessenJ. A.BighamA. W.O’ConnorT. D.FuW.KennyE. E.GravelS.. . . AkeyJ. M. (2012). Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science, 337(6090), 64–69. doi:10.1126/science.1219240.
35.
TrivediM. H.RushA. J.WisniewskiS. R.NierenbergA. A.WardenD.RitzL.. . . FavaM. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. The American Journal of Psychiatry, 163(1), 28–40. doi:10.1176/appi.ajp.163.1.28.
36.
UherR.TanseyK. E.RietschelM.HenigsbergN.MaierW.MorsO.. . . PerlisR. H. (2013). Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies. The American Journal of Psychiatry, 170(2), 207–217. doi:10.1176/appi.ajp.2012.12020237.
37.
WitkinJ. M.TzavaraE. T.DavisR. J.LiX.NomikosG. G. (2005). A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends in Pharmacological Sciences, 26(12), 609–617. doi:10.1016/j.tips.2005.10.006.
38.
WrayN. R.PergadiaM. L.BlackwoodD. H.PenninxB. W.GordonS. D.NyholtD. R.. . . SullivanP. F. (2012). Genome-wide association study of major depressive disorder: New results, meta-analysis, and lessons learned. Molecular Psychiatry, 17(1), 36–48. doi:10.1038/mp.2010.109.
39.
YangJ.LeeS. H.GoddardM. E.VisscherP. M. (2011). GCTA: A tool for genome-wide complex trait analysis. American Journal of Human Genetics, 88(1), 76–82. doi:10.1016/j.ajhg.2010.11.011.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
